Lisata Therapeutics Inc (LSTA)

Currency in USD
4.6000
-0.1100(-2.34%)
Closed·
4.5900-0.0100(-0.22%)
·
LSTA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
4.60004.7500
52 wk Range
1.81004.8918
Key Statistics
Prev. Close
4.6
Open
4.65
Day's Range
4.6-4.75
52 wk Range
1.81-4.8918
Volume
60.71K
Average Volume (3m)
146.37K
1-Year Change
74.2424%
Book Value / Share
1.98
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
LSTA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
11.3333
Upside
+146.38%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year

Lisata Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Lisata Therapeutics Inc Company Profile

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with a range of anti-cancer regimens. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Lisata Therapeutics Inc Earnings Call Summary for Q3/2025

  • Lisata Therapeutics reported Q3 2025 EPS of -$0.49, beating analyst expectations of -$0.59, but stock fell 7.26% in aftermarket trading to $2.17.
  • Operating expenses decreased 17.3% year-over-year to $4.4 million, with R&D expenses down 22.9% and net losses reduced to $4.2 million from $4.9 million.
  • Despite positive earnings surprise of 16.95%, investor concerns persist about ongoing net losses and the company's ability to secure funding for future trials.
  • Management anticipates upcoming phase 3 trials for sirtepotide and is focused on securing pharmaceutical partnerships to fund clinical programs.
  • CEO Dr. David Mazzo highlighted positive results across various studies, while CMO Dr. Kristen Buck emphasized sirtepotide's ability to modify tumor microenvironments.
Last Updated: 11/07/2025, 06:50 AM
Read Full Transcript

Compare LSTA to Peers and Sector

Metrics to compare
LSTA
Peers
Sector
Relationship
P/E Ratio
−2.2x−1.0x−0.5x
PEG Ratio
−0.150.030.00
Price/Book
2.3x1.5x2.6x
Price / LTM Sales
37.9x9.2x3.3x
Upside (Analyst Target)
219.1%100.7%48.1%
Fair Value Upside
Unlock17.4%7.7%Unlock

Analyst Ratings

2 Buy
1 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 11.3333
(+146.38% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Brookline Capital Markets
Hold---DowngradeJan 21, 2026
H.C. Wainwright
Buy15.00+226.09%-MaintainAug 21, 2025
Brookline Capital Markets
Buy32.00+595.65%20.00MaintainJul 15, 2025
H.C. Wainwright
Buy15.00+226.09%-MaintainJun 18, 2025

Earnings

Latest Release
Nov 06, 2025
EPS / Forecast
-0.49 / -0.59
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

LSTA Income Statement

People Also Watch

23.890
BNAI
+7.27%
1.50
SLGB
-13.29%
5.64
IBRX
-4.08%
2.100
EVTV
-4.55%
1.180
VERO
-15.71%

FAQ

What Is the Lisata Therapeutics (LSTA) Stock Price Today?

The Lisata Therapeutics stock price today is 4.6000

What Stock Exchange Does Lisata Therapeutics Trade On?

Lisata Therapeutics is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Lisata Therapeutics?

The stock symbol for Lisata Therapeutics is "LSTA."

What Is the Lisata Therapeutics Market Cap?

As of today, Lisata Therapeutics market cap is 40.58M.

What Is Lisata Therapeutics's Earnings Per Share (TTM)?

The Lisata Therapeutics EPS (TTM) is -2.12.

When Is the Next Lisata Therapeutics Earnings Date?

Lisata Therapeutics will release its next earnings report on Feb 25, 2026.

From a Technical Analysis Perspective, Is LSTA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Lisata Therapeutics Stock Split?

Lisata Therapeutics has split 6 times.

How Many Employees Does Lisata Therapeutics Have?

Lisata Therapeutics has 26 employees.

What is the current trading status of Lisata Therapeutics (LSTA)?

As of Feb 06, 2026, Lisata Therapeutics (LSTA) is trading at a price of 4.6000, with a previous close of 4.6000. The stock has fluctuated within a day range of 4.6000 to 4.7500, while its 52-week range spans from 1.8100 to 4.8918.

What Is Lisata Therapeutics (LSTA) Price Target According to Analysts?

The average 12-month price target for Lisata Therapeutics is USD11.3333, with a high estimate of USD15 and a low estimate of USD4. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +146.38% Upside potential.

What Is the LSTA After Hours Price?

LSTA's last after hours stock price is 4.5900, the stock has decreased by -0.0100, or -0.2200%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.